Exelixis (EXEL) Stock Forecast & Price Target

Compare

2,986 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

EXEL Analyst Ratings

Moderate Buy

11 Buy

7 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Exelixis

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

EXEL Stock 12 Month Forecast

Average Price Target

$44.88

▲(4.15%Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Exelixis in the last 3 months. The average price target is $44.88 with a high forecast of $60.00 and a low forecast of $29.00. The average price target represents a 4.15% change from the last price of $43.09.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"20":"$20","61":"$61","30.25":"$30.3","40.5":"$40.5","50.75":"$50.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44.88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$44.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$29.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[20,30.25,40.5,50.75,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.88,44.19692307692308,45.51384615384615,46.830769230769235,48.14769230769231,49.464615384615385,50.78153846153846,52.098461538461535,53.41538461538462,54.73230769230769,56.04923076923077,57.36615384615385,58.683076923076925,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.88,43.033846153846156,43.18769230769231,43.34153846153846,43.495384615384616,43.64923076923077,43.80307692307692,43.95692307692308,44.110769230769236,44.26461538461539,44.41846153846154,44.572307692307696,44.72615384615385,{"y":44.88,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.88,41.8123076923077,40.744615384615386,39.67692307692308,38.60923076923077,37.541538461538465,36.473846153846154,35.40615384615385,34.33846153846154,33.27076923076923,32.20307692307692,31.135384615384616,30.067692307692308,{"y":29,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.92,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.25,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.22,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.03,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.3,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.12,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.59,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.3,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.39,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.89,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.88,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$60.00

Average Price Target$44.88

Lowest Price Target$29.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$51

Buy

18.36%

Upside

Reiterated

06/24/25

Exelixis's strong financial performance, positive earnings outlook, and strategic pipeline developments drive its high stock score. The technical indicators support mild bullish sentiment, while the valuation suggests fair pricing. The company's robust cash position and strategic initiatives provide a solid foundation for future growth.

Akash TewariJefferies

Jefferies

$42→$50

Buy

16.04%

Upside

Reiterated

06/24/25

Exelixis price target raised to $50 from $42 at JefferiesExelixis price target raised to $50 from $42 at Jefferies

Sudan LoganathanStephens

Stephens

$29→$60

Buy

39.24%

Upside

Upgraded

06/24/25

Exelixis upgraded to Overweight from Equal Weight at StephensExelixis upgraded to Overweight from Equal Weight at Stephens

Andy HsiehWilliam Blair

William Blair

―

Buy

―

Reiterated

06/23/25

Exelixis: Promising Clinical Trial Success and Strong Future Prospects Drive Buy Rating

Jason GerberryBank of America Securities

Bank of America Securities

$46

Hold

6.75%

Upside

Reiterated

06/23/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Legend Biotech (NASDAQ: LEGN), Eli Lilly & Co (NYSE: LLY) and Exelixis (NASDAQ: EXEL)

Stephen WilleyStifel Nicolaus

Stifel Nicolaus

$38

Hold

-11.81%

Downside

Reiterated

06/23/25

Stifel Nicolaus Sticks to Its Hold Rating for Exelixis (EXEL)

Ashwani VermaUBS

UBS

$38

Hold

-11.81%

Downside

Reiterated

06/23/25

Exelixis (EXEL) Gets a Hold from UBS

Silvan TuerkcanCitizens JMP

Citizens JMP

$47→$50

Buy

16.04%

Upside

Reiterated

06/23/25

Exelixis price target raised to $50 from $47 at Citizens JMPExelixis price target raised to $50 from $47 at Citizens JMP

Andrew BerensLeerink Partners

Leerink Partners

―

Hold

―

Reiterated

06/23/25

Cautious Hold Rating for Exelixis Amid STELLAR-303 Trial Results and Regulatory Concerns

Peter LawsonBarclays

Barclays

$29

Hold

-32.70%

Downside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Avidity Biosciences (NASDAQ: RNA) and Exelixis (NASDAQ: EXEL)

Asthika GoonewardeneTruist Financial

Truist Financial

$43→$55

Buy

27.64%

Upside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Exelixis (NASDAQ: EXEL) and Abbott Laboratories (NYSE: ABT)

Robert BurnsH.C. Wainwright

H.C. Wainwright

$47

Buy

9.07%

Upside

Reiterated

06/23/25

Analysts Are Bullish on Top Healthcare Stocks: Wave Life Sciences (WVE), Lineage Therap (LCTX)

Derek ArchilaWells Fargo

Wells Fargo

$36

Hold

-16.45%

Downside

Reiterated

06/22/25

Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL) and Larimar Therapeutics (NASDAQ: LRMR)

David LebowitzCiti

Citi

$56

Buy

29.96%

Upside

Reiterated

05/22/25

Exelixis's Growth Potential Highlighted by Promising STELLAR-002 Trial Results and Buy Rating

Michael SchmidtGuggenheim

Guggenheim

$42→$45

Buy

4.43%

Upside

Reiterated

05/14/25

Exelixis price target raised to $45 from $42 at GuggenheimExelixis price target raised to $45 from $42 at Guggenheim

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$51

Buy

18.36%

Upside

Reiterated

06/24/25

Akash TewariJefferies

Jefferies

$42→$50

Buy

16.04%

Upside

Reiterated

06/24/25

Exelixis price target raised to $50 from $42 at JefferiesExelixis price target raised to $50 from $42 at Jefferies

Sudan LoganathanStephens

Stephens

$29→$60

Buy

39.24%

Upside

Upgraded

06/24/25

Exelixis upgraded to Overweight from Equal Weight at StephensExelixis upgraded to Overweight from Equal Weight at Stephens

Andy HsiehWilliam Blair

William Blair

―

Buy

―

Reiterated

06/23/25

Exelixis: Promising Clinical Trial Success and Strong Future Prospects Drive Buy Rating

Jason GerberryBank of America Securities

Bank of America Securities

$46

Hold

6.75%

Upside

Reiterated

06/23/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Legend Biotech (NASDAQ: LEGN), Eli Lilly & Co (NYSE: LLY) and Exelixis (NASDAQ: EXEL)

Stephen WilleyStifel Nicolaus

Stifel Nicolaus

$38

Hold

-11.81%

Downside

Reiterated

06/23/25

Stifel Nicolaus Sticks to Its Hold Rating for Exelixis (EXEL)

Ashwani VermaUBS

UBS

$38

Hold

-11.81%

Downside

Reiterated

06/23/25

Exelixis (EXEL) Gets a Hold from UBS

Silvan TuerkcanCitizens JMP

Citizens JMP

$47→$50

Buy

16.04%

Upside

Reiterated

06/23/25

Exelixis price target raised to $50 from $47 at Citizens JMPExelixis price target raised to $50 from $47 at Citizens JMP

Andrew BerensLeerink Partners

Leerink Partners

―

Hold

―

Reiterated

06/23/25

Cautious Hold Rating for Exelixis Amid STELLAR-303 Trial Results and Regulatory Concerns

Peter LawsonBarclays

Barclays

$29

Hold

-32.70%

Downside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Avidity Biosciences (NASDAQ: RNA) and Exelixis (NASDAQ: EXEL)

Asthika GoonewardeneTruist Financial

Truist Financial

$43→$55

Buy

27.64%

Upside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Exelixis (NASDAQ: EXEL) and Abbott Laboratories (NYSE: ABT)

Robert BurnsH.C. Wainwright

H.C. Wainwright

$47

Buy

9.07%

Upside

Reiterated

06/23/25

Analysts Are Bullish on Top Healthcare Stocks: Wave Life Sciences (WVE), Lineage Therap (LCTX)

Derek ArchilaWells Fargo

Wells Fargo

$36

Hold

-16.45%

Downside

Reiterated

06/22/25

Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL) and Larimar Therapeutics (NASDAQ: LRMR)

David LebowitzCiti

Citi

$56

Buy

29.96%

Upside

Reiterated

05/22/25

Exelixis's Growth Potential Highlighted by Promising STELLAR-002 Trial Results and Buy Rating

Michael SchmidtGuggenheim

Guggenheim

$42→$45

Buy

4.43%

Upside

Reiterated

05/14/25

Exelixis price target raised to $45 from $42 at GuggenheimExelixis price target raised to $45 from $42 at Guggenheim

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Exelixis

1 Month

xxx

Success Rate

17/27 ratings generated profit

Average Return

+7.98%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 62.96% of your transactions generating a profit, with an average return of +7.98% per trade.

3 Months

xxx

Success Rate

24/27 ratings generated profit

Average Return

+26.13%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 88.89% of your transactions generating a profit, with an average return of +26.13% per trade.

1 Year

Silvan TuerkcanCitizens JMP

Success Rate

33/37 ratings generated profit

Average Return

+30.87%

reiterated a buy rating 5 days ago

Copying Silvan Tuerkcan's trades and holding each position for 1 Year would result in 89.19% of your transactions generating a profit, with an average return of +30.87% per trade.

2 Years

xxx

Success Rate

27/27 ratings generated profit

Average Return

+69.87%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +69.87% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EXEL Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, EXEL has received 26 Buy Ratings, 17 Hold Ratings, and 0 Sell Ratings. EXEL average Analyst price target in the past 3 months is 44.88.

Each month's total comprises the sum of three months' worth of ratings.

EXEL Financial Forecast

EXEL Earnings Forecast

Next quarter’s earnings estimate for EXEL is $0.64 with a range of $0.58 to $0.74. The previous quarter’s EPS was $0.62. EXEL beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.14% of the time in the same period. In the last calendar year EXEL has Outperformed its overall industry.

EXEL Sales Forecast

Next quarter’s sales forecast for EXEL is $576.20M with a range of $549.00M to $630.38M. The previous quarter’s sales results were $555.45M. EXEL beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.50% of the time in the same period. In the last calendar year EXEL has Outperformed its overall industry.

EXEL Stock Forecast FAQ

What is EXEL’s average 12-month price target, according to analysts?

Based on analyst ratings, Exelixis’s 12-month average price target is 44.88.

What is EXEL’s upside potential, based on the analysts’ average price target?

Exelixis has 4.15% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is EXEL a Buy, Sell or Hold?

Exelixis has a consensus rating of Moderate Buy which is based on 11 buy ratings, 7 hold ratings and 0 sell ratings.

What is Exelixis’s price target?

The average price target for Exelixis is 44.88. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $60.00 ,the lowest forecast is $29.00. The average price target represents 4.15% Increase from the current price of $43.09.

What do analysts say about Exelixis?

Exelixis’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of EXEL?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Exelixis (EXEL) Stock Forecast & Price Target

EXEL Analyst Ratings

EXEL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Exelixis

EXEL Analyst Recommendation Trends

EXEL Financial Forecast

EXEL Earnings Forecast

EXEL Sales Forecast

EXEL Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts